scholarly journals Insulin use and fracture risk in patients with type 2 diabetes: A meta‑analysis of 138,690�patients

2019 ◽  
Author(s):  
Yuxian Zhang ◽  
Qiuying Chen ◽  
Yuying Liang ◽  
Yuhao Dong ◽  
Xiaokai Mo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fracture Risk ◽  
Meta Analysis ◽  
Insulin Use

scholarly journals Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis

2017 ◽  
Vol Volume 13 ◽  
pp. 455-468 ◽  
Author(s):  
Ardeshir Moayeri ◽  
Mahmoud Mohamadpour ◽  
Seyedeh Mousavi ◽  
Ehsan Shirzadpour ◽  
Safoura Mohamadpour ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fracture Risk ◽  
Meta Analysis

scholarly journals Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Eladio Losada-Grande ◽  
Samuel Hawley ◽  
Berta Soldevila ◽  
Daniel Martinez-Laguna ◽  
Xavier Nogues ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fracture Risk ◽  
Cohort Analysis ◽  
Matched Cohort ◽  
Insulin Use

scholarly journals Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Chengxia Kan ◽  
Yang Zhang ◽  
Fang Han ◽  
Qian Xu ◽  
Tongtong Ye ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Mortality Risk ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Antidiabetic Agents ◽  
Medical Databases ◽  
Insulin Use ◽  
Lower Mortality Risk

AimsWe conducted a systematic review and meta-analysis to assess various antidiabetic agents’ association with mortality in patients with type 2 diabetes (T2DM) who have coronavirus disease 2019 (COVID-19).MethodsWe performed comprehensive literature retrieval from the date of inception until February 2, 2021, in medical databases (PubMed, Web of Science, Embase, and Cochrane Library), regarding mortality outcomes in patients with T2DM who have COVID-19. Pooled OR and 95% CI data were used to assess relationships between antidiabetic agents and mortality.ResultsEighteen studies with 17,338 patients were included in the meta-analysis. Metformin (pooled OR, 0.69; P=0.001) and sulfonylurea (pooled OR, 0.80; P=0.016) were associated with lower mortality risk in patients with T2DM who had COVID-19. However, patients with T2DM who had COVID-19 and received insulin exhibited greater mortality (pooled OR, 2.20; P=0.002). Mortality did not significantly differ (pooled OR, 0.72; P=0.057) between DPP-4 inhibitor users and non-users.ConclusionsMetformin and sulfonylurea could be associated with reduced mortality risk in patients with T2DM who have COVID-19. Furthermore, insulin use could be associated with greater mortality, while DPP-4 inhibitor use could not be. The effects of antidiabetic agents in patients with T2DM who have COVID-19 require further exploration.Systematic Review RegistrationPROSPERO (identifier, CRD42021242898).

Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta‐analysis

2020 ◽  
Vol 159 ◽  
pp. 107990 ◽  
Author(s):  
Zhen Zhang ◽  
Yang Cao ◽  
Yujia Tao ◽  
Meng E ◽  
Jiahao Tang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fracture Risk ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document